JP2022513913A - がん免疫療法のためのラビリンチンベースのペプチドとその使用 - Google Patents
がん免疫療法のためのラビリンチンベースのペプチドとその使用 Download PDFInfo
- Publication number
- JP2022513913A JP2022513913A JP2021534341A JP2021534341A JP2022513913A JP 2022513913 A JP2022513913 A JP 2022513913A JP 2021534341 A JP2021534341 A JP 2021534341A JP 2021534341 A JP2021534341 A JP 2021534341A JP 2022513913 A JP2022513913 A JP 2022513913A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- labyrinthine
- variant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 1369
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 167
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 546
- 230000000890 antigenic effect Effects 0.000 claims abstract description 289
- 229960005486 vaccine Drugs 0.000 claims abstract description 217
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 172
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 169
- 238000000034 method Methods 0.000 claims abstract description 77
- 150000001413 amino acids Chemical class 0.000 claims description 858
- 206010028980 Neoplasm Diseases 0.000 claims description 119
- 201000011510 cancer Diseases 0.000 claims description 82
- 238000011282 treatment Methods 0.000 claims description 70
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 239000003981 vehicle Substances 0.000 claims description 47
- 239000002671 adjuvant Substances 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 12
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 230000002434 immunopotentiative effect Effects 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000000277 virosome Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 238000010586 diagram Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 804
- 238000007792 addition Methods 0.000 description 65
- 238000003780 insertion Methods 0.000 description 52
- 230000037431 insertion Effects 0.000 description 52
- 238000006467 substitution reaction Methods 0.000 description 52
- 238000002347 injection Methods 0.000 description 50
- 239000007924 injection Substances 0.000 description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 44
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 44
- 238000002255 vaccination Methods 0.000 description 39
- 239000011780 sodium chloride Substances 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 150000008574 D-amino acids Chemical class 0.000 description 35
- 150000008575 L-amino acids Chemical class 0.000 description 35
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 35
- 235000008206 alpha-amino acids Nutrition 0.000 description 35
- 201000010099 disease Diseases 0.000 description 33
- 230000003902 lesion Effects 0.000 description 30
- 231100000419 toxicity Toxicity 0.000 description 25
- 230000001988 toxicity Effects 0.000 description 25
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 230000033289 adaptive immune response Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 208000009956 adenocarcinoma Diseases 0.000 description 17
- 229930182490 saponin Natural products 0.000 description 17
- 150000007949 saponins Chemical class 0.000 description 17
- 235000017709 saponins Nutrition 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000523 sample Substances 0.000 description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 210000005006 adaptive immune system Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000009121 systemic therapy Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 102000046157 human CSF2 Human genes 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100022108 Aspartyl/asparaginyl beta-hydroxylase Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000901030 Homo sapiens Aspartyl/asparaginyl beta-hydroxylase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001651 emery Inorganic materials 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000009459 flexible packaging Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 231100001156 grade 3 toxicity Toxicity 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- -1 trisbase-65 Chemical compound 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 240000007241 Agrostis stolonifera Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 206010065305 Cancer in remission Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009557 abdominal ultrasonography Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010025220 aspartic acid 2-oxoglutarate-dependent dioxygenase Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000011375 palliative radiation therapy Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940031734 peptide cancer vaccine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940031762 synthetic peptide cancer vaccine Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
この出願は、その開示を、その全体について出典明示によりここに援用する、2018年12月13日に出願された米国仮特許出願第62/779377号の優先権を主張する。
ASCIIテキストファイルでの次の提出書類の内容を、その全体について出典明示によりここに援用する:コンピュータ可読形式(CRF)の配列表(ファイル名:185722000140SEQLIST.TXT、記録日:2019年12月10日、サイズ:8KB)。
幾つかの態様では、本出願は、一又は複数のラビリンチン由来ペプチドを含む抗原性組成物に関する。他の態様では、本出願は、一又は複数のラビリンチン由来ペプチドを含み、ここで、各ペプチドがT細胞エピトープ及び/又はB細胞エピトープを含む、抗原性組成物に関する。他の態様では、本出願は、ここに開示される組成物で対象にワクチン接種することによって産生される抗体に関する。
ここで使用される「実質的に相同」という用語は、参照配列と比較した場合のここに開示される配列の配列類似性を指し、配列は、参照又はその一部と少なくとも約85%の類似性(例えば、相同性)、例えば、少なくとも約86%の類似性、87%の類似性、88%の類似性、89%の類似性、90%の類似性、91%の類似性、92%の類似性、93%の類似性、94%の類似性、95%の類似性、96%の類似性、97%の類似性、98%の類似性、99%の類似性、又は100%の類似性の何れかを有する。配列類似性を決定するための方法は、例えば、Pearson, W. R., Curr Protoc Bioinformatics, 2013に記載されているように、当該技術分野で知られている。
本出願は、幾つかの態様では、一又は複数のラビリンチン由来ペプチドを含む抗原性組成物を提供する。ラビリンチンは、配列番号:1(表1に示す)に記載されている255アミノ酸配列を有するタンパク質である。junctate、humbug、及びヒトアスパルチルベータヒドロキシラーゼ(HAAH)を含む、ラビリンチンに関連する転写バリアントが知られている(例えば、その全体が出典明示によりここに援用される米国特許第6166176号を参照のこと)。
幾つかの実施態様では、ここに開示される抗原性組成物に含まれる一又は複数のラビリンチン由来ペプチドのうちの少なくとも一をコードする一又は複数の核酸を含む核酸組成物が提供される。幾つかの実施態様では、核酸組成物は、少なくとも二以上のラビリンチン由来ペプチドをコードする核酸を含む。幾つかの実施態様では、核酸組成物は、少なくとも三以上のラビリンチン由来ペプチドをコードする核酸を含む。幾つかの実施態様では、核酸組成物は、四のラビリンチン由来ペプチドをコードする核酸を含む。
幾つかの実施態様では、(a)ここに記載の抗原性組成物の何れか一の有効量の抗原性組成物と;(b)薬学的に許容されるビヒクルを含むワクチン組成物が提供される。
本開示は、幾つかの態様では、キット、医薬品、及び組成物(薬学的組成物及び単位調剤など)を含む、ここに開示される抗原性組成物を含む組成物を提供する。幾つかの態様では、本開示は、キット、医薬品、及びそれらの組成物(薬学的組成物及び単位調剤など)を含む、ここに開示される抗原性組成物を含むワクチン組成物を提供する。
本開示は、幾つかの態様では、ここに記載されるワクチン組成物の使用方法を提供する。幾つかの態様では、本開示は、治療を必要とする個体のがんを治療するための方法であって、ここに記載のワクチン組成物を個体に投与することを含む方法を提供する。他の態様では、本開示は、予防を必要とする個体のがんを予防するための方法であって、ここに記載のワクチン組成物を個体に投与することを含む方法を提供する。幾つかの実施態様では、がんは、ラビリンチン陽性がんである。幾つかの実施態様では、がんは、ラビリンチン陽性腺がんなどの腺がんである。
本開示は、幾つかの態様では、例えば宿主動物において、インビボで抗体を産生する方法を提供する。幾つかの実施態様では、該方法は、ここでの開示に係る抗原性組成物を宿主動物に投与することを含む。幾つかの実施態様では、該方法は、ここでの開示に係る核酸組成物を宿主動物に投与することを含む。幾つかの実施態様では、該方法は、ここでの開示に係るワクチン組成物を宿主動物に投与することを含む。
この実施例は、ここでの開示に係るラビリンチン由来ペプチドのデザイン、合成、及び選択の定式化を実証する。
ラビリンチン由来ペプチドを、B細胞及びT細胞獲得免疫系応答を生じるようにデザインした。ラビリンチンアミノ酸配列(配列番号:1)を開始テンプレートとして使用して、13のラビリンチン由来ペプチドをデザインし、4つのラビリンチン由来ペプチド候補を、更なる評価及び開発のために選択した(配列番号:29、配列番号:30、配列番号:31、及び配列番号:32)。選択した4つのラビリンチン由来ペプチド候補は、B細胞性適応免疫系を介して既知の免疫原性を有するアミノ酸配列を含み、MHCII複合体溝への予測される結合がT細胞性適応免疫系応答をまたトリガーすることを確認するための研究を行なった。
4つのラビリンチン由来ペプチド候補(配列番号:29、配列番号:30、配列番号:31、及び配列番号:32)を合成した。各ラビリンチン由来ペプチド候補配列は、質量分析を使用して確認した。具体的には、エレクトロスプレーイオン化質量分析法を使用して、各サンプルの親イオンm/zスペクトルを取得し(配列番号:29-32のスペクトルをそれぞれ図1A-1Dに示す)、続いてタンデム質量分析法を使用して、イオン分裂データを収集し、各ラビリンチン由来ペプチド候補のペプチド配列を確認した(データは示さず)。
各ラビリンチン由来ペプチド候補の溶解度を、超純水、0.1MのPBS(PBS;pH7.4)、及びジメチルスルホキシド(DMSO;分析グレード)において目視検査によって評価した。表4に報告されるように、0.1mg/mL溶媒未満の溶解度を「未溶解」と定義し、0.1mg/mL以上の溶解度を「溶解」と定義した。測定した溶解度の濃度範囲は、利用可能な場合は「溶解」分類の下に提供される(表4)。
この実施例は、4つのラビリンチン由来ペプチド(配列番号:29-32)を含むワクチン(LabVax 3(22)-23)による腫瘍増殖の阻害を実証する。
ここに記載のペプチドの投与後の抗体の産生を試験するために、12匹のBalb/cマウスを4つの処置群に分け、各処置群を配列番号:29-32の一つの注射を受けるように割り当てた。表8に示されるように、各処置群において陽性クローンを特定した。
この実施例は、腺がんを有する患者における4ペプチドのラビリンチンがんワクチン(LabVax3(22)-23)の第I相試験を実証している。ワクチンの4つのペプチドは、配列番号:29-32である。
Claims (34)
- 一又は複数のラビリンチン由来ペプチドを含む抗原性組成物であって、各ラビリンチン由来ペプチドが、T細胞エピトープとB細胞エピトープの一又は複数を含む、抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドのそれぞれが、T細胞エピトープとB細胞エピトープを含む、請求項1に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドが8から25アミノ酸長である、請求項1又は2に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドがラビリンチンの一部と実質的に相同である、請求項1から3の何れか一項に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドのそれぞれが非末端プロリン残基を含む、請求項1から4の何れか一項に記載の抗原性組成物。
- (a)配列番号:25又はそのバリアントを含む第一のペプチド;
(b)配列番号:26又はそのバリアントを含む第二のペプチド;
(c)配列番号:27又はそのバリアントを含む第三のペプチド;及び
(d)配列番号:28又はそのバリアントを含む第四のペプチド
からなる群から選択される一又は複数のラビリンチン由来ペプチドを含み、
一又は複数のラビリンチン由来ペプチドが12から25アミノ酸長であり、かつ
各ペプチドが、T細胞エピトープとB細胞エピトープを含む、抗原性組成物。 - 第一のペプチドが配列番号:25を含む、請求項6に記載の抗原性組成物。
- 第二のペプチドが配列番号:26を含む、請求項6又は7に記載の抗原性組成物。
- 第三のペプチドが配列番号:27を含む、請求項6から8の何れか一項に記載の抗原性組成物。
- 第四のペプチドが配列番号:28を含む、請求項6から9の何れか一項に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドが21から24アミノ酸長である、請求項6から10の何れか一項に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドが22又は23アミノ酸長である、請求項6から11の何れか一項に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドがラビリンチンの一部と実質的に相同である、請求項6から12の何れか一項に記載の抗原性組成物。
- 第一のペプチドが、配列番号:29、又は配列番号:29に対して置換、欠失、挿入、及び/若しくは付加された一若しくは二のアミノ酸を有するそのバリアントである、請求項6から13の何れか一項に記載の抗原性組成物。
- 第一のペプチドが配列番号:29である、請求項6から14の何れか一項に記載の抗原性組成物。
- 第二のペプチドが、配列番号:30、又は配列番号:30に対して置換、欠失、挿入、及び/若しくは付加された一若しくは二のアミノ酸を有するそのバリアントである、請求項6から15の何れか一項に記載の抗原性組成物。
- 第二のペプチドが配列番号:30である、請求項6から16の何れか一項に記載の抗原性組成物。
- 第三のペプチドが、配列番号:31、又は配列番号:31に対して置換、欠失、挿入、及び/若しくは付加された一若しくは二のアミノ酸を有するそのバリアントである、請求項6から17の何れか一項に記載の抗原性組成物。
- 第三のペプチドが配列番号:31である、請求項6から18の何れか一項に記載の抗原性組成物。
- 第四のペプチドが、配列番号:32、又は配列番号:32に対して置換、欠失、挿入、及び/若しくは付加された一若しくは二のアミノ酸を有するそのバリアントである、請求項6から19の何れか一項に記載の抗原性組成物。
- 第四のペプチドが配列番号:32である、請求項6から20の何れか一項に記載の抗原性組成物。
- 一又は複数のラビリンチン由来ペプチドのうちの少なくとも一がリンカーにコンジュゲートされている、請求項6から21の何れか一項に記載の抗原性組成物。
- 抗原性組成物が二以上のラビリンチン由来ペプチドを含む、請求項6から22の何れか一項に記載の抗原性組成物。
- 抗原性組成物が三以上のラビリンチン由来ペプチドを含む、請求項6から23の何れか一項に記載の抗原性組成物。
- 抗原性組成物が四のラビリンチン由来ペプチドを含む、請求項6から24の何れか一項に記載の抗原性組成物。
- 請求項1から25の何れか一項に記載の抗原性組成物に含まれる一又は複数のラビリンチン由来ペプチドのうちの少なくとも一をコードする一又は複数の核酸を含む核酸組成物。
- (a)有効量の、請求項1から25の何れか一項に記載の抗原性組成物と;
(b)薬学的に許容されるビヒクル
を含むワクチン組成物。 - 薬学的に許容されるビヒクルが、水性懸濁液、油性懸濁液、乳濁液、リポソーム、ビロソーム、及びナノ粒子からなる群から選択される、請求項27に記載のワクチン組成物。
- 薬学的に許容されるビヒクルが添加物を含む、請求項27又は28に記載のワクチン組成物。
- 薬学的に許容されるビヒクルがアジュバントを含む、請求項27から29の何れか一項に記載のワクチン組成物。
- アジュバントが免疫増強アジュバントである、請求項30に記載のワクチン組成物。
- 治療を必要とする個体におけるがんを治療するための方法であって、請求項27から31の何れか一項に記載のワクチン組成物を個体に投与することを含む、方法。
- 免疫チェックポイント阻害剤を個体に投与することを更に含む、請求項32に記載の方法。
- 宿主動物において抗体を産生させる方法であって、請求項1から25の何れか一項に記載の抗原性組成物、請求項26に記載の核酸組成物、又は請求項27から33の何れか一項に記載のワクチン組成物を宿主動物に投与することを含み、それによって抗体を産生させる、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779377P | 2018-12-13 | 2018-12-13 | |
US62/779,377 | 2018-12-13 | ||
PCT/US2019/066264 WO2020123964A1 (en) | 2018-12-13 | 2019-12-13 | Labyrinthin-based peptides for cancer immunotherapies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513913A true JP2022513913A (ja) | 2022-02-09 |
JPWO2020123964A5 JPWO2020123964A5 (ja) | 2022-12-21 |
Family
ID=71077093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021534341A Pending JP2022513913A (ja) | 2018-12-13 | 2019-12-13 | がん免疫療法のためのラビリンチンベースのペプチドとその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220409709A1 (ja) |
EP (1) | EP3894432A4 (ja) |
JP (1) | JP2022513913A (ja) |
KR (1) | KR20210131995A (ja) |
CN (1) | CN113412275A (ja) |
AU (1) | AU2019397539A1 (ja) |
CA (1) | CA3123396A1 (ja) |
IL (1) | IL283933A (ja) |
MX (1) | MX2021007074A (ja) |
TW (1) | TW202039536A (ja) |
WO (1) | WO2020123964A1 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166176A (en) * | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
US6190670B1 (en) * | 1999-04-12 | 2001-02-20 | Immtech International Inc. | Use of mCRP to enhance immune responses |
WO2011116014A2 (en) * | 2010-03-15 | 2011-09-22 | Mission Therapeutics, Inc. | Humanized antibodies to labyrinthin and uses thereof |
EP2607374A1 (en) * | 2011-12-21 | 2013-06-26 | Sanofi | Method for recombinant production of labyrinthopeptins and functional derivatives thereof |
-
2019
- 2019-12-13 MX MX2021007074A patent/MX2021007074A/es unknown
- 2019-12-13 KR KR1020217021896A patent/KR20210131995A/ko unknown
- 2019-12-13 CN CN201980091552.9A patent/CN113412275A/zh active Pending
- 2019-12-13 US US17/309,648 patent/US20220409709A1/en active Pending
- 2019-12-13 WO PCT/US2019/066264 patent/WO2020123964A1/en unknown
- 2019-12-13 TW TW108145889A patent/TW202039536A/zh unknown
- 2019-12-13 EP EP19895424.0A patent/EP3894432A4/en active Pending
- 2019-12-13 CA CA3123396A patent/CA3123396A1/en active Pending
- 2019-12-13 JP JP2021534341A patent/JP2022513913A/ja active Pending
- 2019-12-13 AU AU2019397539A patent/AU2019397539A1/en active Pending
-
2021
- 2021-06-13 IL IL283933A patent/IL283933A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220409709A1 (en) | 2022-12-29 |
CA3123396A1 (en) | 2020-06-18 |
MX2021007074A (es) | 2021-10-13 |
TW202039536A (zh) | 2020-11-01 |
KR20210131995A (ko) | 2021-11-03 |
EP3894432A1 (en) | 2021-10-20 |
WO2020123964A1 (en) | 2020-06-18 |
IL283933A (en) | 2021-07-29 |
AU2019397539A1 (en) | 2021-07-15 |
CN113412275A (zh) | 2021-09-17 |
EP3894432A4 (en) | 2023-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Slovin et al. | Carbohydrate vaccines as immunotherapy for cancer | |
Ragupathi et al. | Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21 | |
JP2018538265A (ja) | 癌を治療するための方法及び組成物 | |
US20170232085A1 (en) | Companion animal treatments | |
Ragupathi et al. | A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers | |
US9114099B2 (en) | Vaccine for the prevention of breast cancer recurrence | |
BRPI1012890B1 (pt) | Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit | |
KR20240008422A (ko) | 잔류물 최적화를 이용한 최적화된 펩티드 백신의 조성 및 방법 | |
Guthmann et al. | Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity | |
Gerard et al. | A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors | |
Mazumder et al. | Primary immunoprevention of epithelial ovarian carcinoma by vaccination against the extracellular domain of anti-Müllerian hormone receptor II | |
Zhao et al. | Different protective efficacies of a novel antigen-specific DNA vaccine encoding chicken type Ⅱ collagen via intramuscular, subcutaneous, and intravenous vaccination against experimental rheumatoid arthritis | |
US20190117749A1 (en) | PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS | |
JP6385280B2 (ja) | 自家癌細胞ワクチン | |
Sher et al. | Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine | |
Lin et al. | Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells | |
JP2022513913A (ja) | がん免疫療法のためのラビリンチンベースのペプチドとその使用 | |
JP2022516639A (ja) | ネオエピトープを標的とするワクチン | |
RU2607379C2 (ru) | Раковый антиген | |
Son et al. | T/Tn immunotherapy avoiding immune deviation | |
WO2021138582A1 (en) | Fusion proteins and methods of use thereof | |
Huo et al. | Pre-clinical safety evaluation of heat shock protein 65–MUC1 peptide fusion protein | |
US20240091328A1 (en) | Formulations and methods for mhc-i restricted epitope immunization | |
US11338025B2 (en) | Vaccine therapy for treatment of endometrial and ovarian cancer | |
Tijtgat et al. | Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221213 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240430 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |